G1 Therapeutics Stock
-
Your prediction
G1 Therapeutics Stock
G1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Pros and Cons of G1 Therapeutics in the next few years
Pros
Cons
Performance of G1 Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| G1 Therapeutics | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financial overview of G1 Therapeutics, trading under the symbol GTHX, presents a somewhat turbulent picture typical of many firms within the Biotechnology and Medical Research sector. The company's journey reflects both its ambitious endeavors in drug development and the inherent risks associated with such pursuits. Investors and analysts often find themselves weighing the potential rewards against considerable losses reflected in the financial statements. A closer look reveals several strengths alongside notable weaknesses that could influence future decision-making.
Pros of G1 Therapeutics Financials
Revenue Generation: Recent reports indicate that G1 Therapeutics recorded a total revenue of approximately $82.5 million in 2023. This is a notable achievement given the industry's often lengthy road to commercialization of pharmaceuticals. Coupled with a quarterly revenue growth year-over-year of 11.8%, it suggests that the company is making strides in its sales performance, hinting at a positive trajectory for upcoming quarters.
Comments
